FDA Brief

Warning letters Devices

FDA warning letter to

Global Medical Production Co Ltd

High riskIssued Nov 16, 2021Posted Dec 21, 2021Center for Devices and Radiological Health

FDA warns Chinese device maker Global Medical Production that sterile surgical instruments lacked design controls, validation and records, and blocks US imports.

What happened

FDA inspected the firm's Jiaxing, China facility from July 15 through July 30, 2021 and found the quality system for its electrosurgical scissors, graspers and Veress needles did not meet US quality system rules. Among other things, the firm had no design control procedures or design records, could not show results from the heat-sealing process validation, and had no procedure for reporting device adverse events to FDA. The firm also held warehouse product labeled "sterile" that had not been sterilized, and several findings repeat violations from an April 2015 inspection.

What FDA found

  1. The firm had no written design control procedures and no records showing design and development work for its private-label devices sold in the US.

    21 CFR 820.30(a)
  2. Its nonconforming product procedure did not require evaluating or disposing of bad product, deciding whether an investigation was needed, or notifying the people responsible.

    21 CFR 820.90(a)
  3. The firm could not produce the objective data and results from the performance qualification of its heat-sealing process, which cannot be fully verified by later inspection and testing.

    21 CFR 820.75(a)
  4. There was no maintenance schedule for the production room HEPA air filters or for the water purifier used in ultrasonic cleaning of device components.

    21 CFR 820.70(g)(1)
  5. Warehouse product meant for the US was labeled "sterile" when it had not been sterilized, and the firm had no process to mark unprocessed product as non-sterile.

    21 CFR 820.86
  6. The firm had no device master records or device history records for these devices and no written procedure for reporting device adverse events to FDA.

    21 CFR 820.181 and 820.184; 21 CFR 803.17

What FDA wants

FDA asks the firm to reply in writing within 15 business days describing the specific steps taken to fix each violation, how it will prevent repeat violations, and a timetable for any work still ongoing, with English translations of non-English documents. FDA also says the devices will be held at the US border (detained without physical examination) until the violations are corrected.

Who should pay attention

  • US private-label brands and distributors selling this firm's surgical devices
  • hospitals and surgery centers buying electrosurgical scissors, graspers or Veress needles
  • companies that rely on a contract manufacturer's design records and sterilization status labels

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  2. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  3. Unilam Co., LTD

    Unilam Co., LTD's UV sunlamps violate quality-system and radiation-safety testing rules, FDA says.

    High risk
  4. Nipro Renal Solutions USA, Corporation

    Nipro Renal Solutions USA released hemodialysis dialysate lots with out-of-spec endotoxin (bacterial toxin) and had widespread quality-system failures, FDA says.

    High risk